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LENGTH OF STAY AND COSTS ASSOCIATED WITH
SURGICAL SITE INFECTIONS IN COLON PROCEDURES IN A
LARGE U.S. DATABASE
Turpin RS1, Mahmoud N2,Yang G3, Saunders W3
1Merck & Co., Inc, West Point, PA, USA, 2Hospital of the University of
Pennsylvania, Philadelphia, PA, USA, 3Premier, Inc, Charlotte, NC, USA
OBJECTIVES: During the 1990’s, colorectal patients in the U.S.
experienced 6.5 extra hospital days and $3089 in costs attribut-
able to surgical wound infections, but no updated information
is available. We utilized a large U.S. hospital database to iden-
tify the variables associated with increased length of stay (LOS)
and costs for colon procedures. METHODS: We utilized a ret-
rospective comparative national database to assess LOS and
costs in 196 hospitals from 1/1/2005 through June 30, 2006. The
study population was all patients >18 years, identiﬁed via ICD-
9 & CPT procedure codes for elective colon procedures. Patients
given cefotetan as surgical prophylaxis were compared to
patients given commonly used prophylactic antimicrobials,
including cefazolin/metronidazole. Patient demographics, surgi-
cal procedure, primary diagnosis, co-morbidities, and patient
severity were examined as predictors of LOS <7 days and cost
>=$15,000 using logistic regression. Patient severity was classi-
ﬁed by APR-DRG severity of illness subclasses and SENIC risk
index for infection. RESULTS: Hospitals were mostly urban
(90%) with >300 beds (70%), and 58% were non-teaching.
They represented each region of the U.S., though predominantly
Mid- and South-Atlantic (44.0). The 23,801 unique patients
were 51% >65 years, 53% female, and 73% white. The overall
infection rate was 3.3%; mean LOS 7.0 (SD 5.7); mean total cost
$12,871 (SD $11,295); and mean daily cost $2015 (SD $917).
In an adjusted model, compared to cefazolin/metronidazole,
cefotetan is associated with a lower rate of LOS 7 days or more
(OR = 0.92; p = 0.007) and total cost >=$15,000 (OR = 0.71; 
p < 0.001). Additional predictors of greater LOS and costs are
elevated severity (OR = 9.02 & 11.53) and SENIC scores (OR
= 1.51 & 4.12), age <75 (OR = 2.18 & 1.66), and non-white
ethnicity (OR = 1.31 & 1.16). CONCLUSION: Cefotetan 
has limited availability and substitutions are increasingly uti-
lized. Yet in elective colon procedures, cefotetan used as surgical
prophylaxis is associated with lower LOS and costs compared to
cefazolin/metronidazole.
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OBJECTIVES: To estimate severe sepsis (SS) incidence, health
resource use and costs during hospitalization in Brazilian private
health care system, and to verify economic impact of drotreco-
gin-alfa activated (DrotAA) treatment. METHODS: We per-
formed a retrospective data analysis of private health plans’
electronic claims between April 2005 and March 2006. SS were
deﬁned according to 2001 ACP/SCCM criteria. Collected data
were: total length of stay (LOS), length of ICU stay (ICU–LOS),
maximum organ dysfunction number achieved during hospital
stay (MOD), average cost per day, and total cost per patient.
RESULTS: Incidence of SS hospitalization among 5.2 million
health plan beneﬁciaries was 2,12/1000, summing up 11,067
patients/year. Cost/day and total hospital cost increased propor-
tionally to MOD: from R$ 2398.00 (patients with 1MOD) to
R$ 2900.00 (4MOD) and from R$ 43,010.00 to R$ 64,276.00.
ICU-LOS varied from 8 to 10 and total-LOS from 18 to 22 days.
Patients with SS with 1MOD represented >75% of the total
number, while with 4MOD were 2% of total population.
DrotAA were given to 1.3% of total SS patients (148). Fifty-three
percent of DrotAA patients had MOD≥ 2, compared to 19% of
the non-DrotAA patients. Average cost of DrotAA per patient
was R$ 38,809.00. Total hospital cost for the whole group of
patients was R$ 498,079,803.00. Thus, DrotAA cost represented
1.2% of hospital costs related to SS. CONCLUSION: Costs with
SS are substantial, and increase with disease severity. Since there
is minor increase in LOS, an increase in daily medical resources
is expected. Patient number receiving DrotAA, and consequently,
additional cost are small relative to SS baseline cost. Thus, pre-
viously described DrotAA beneﬁt on survival and organ dys-
function may outweigh drug costs.
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COST-EFFECTIVENESS OF SUBSTITUTING LAMIVUDINE
(LVD) WITH ENTECAVIR (ETV) IN CHRONIC HEPATITIS B
(CHB) PATIENTS IN THE PUBLIC SECTOR OF HONG KONG
Lee KK1, Lee VWY1,Yuan Y2
1The Chinese University of Hong Kong, Hong Kong, China, 2Bristol
Myers Squibb International Corporation, Plainsboro, NJ, USA
OBJECTIVES: To study the cost-effectiveness if LVD were
replaced by ETV in a group of patients with CHB in a public
hospital in Hong Kong. METHODS: From a public hospital per-
spective, a decision analytic model was used to study the cost-
effectiveness of 2 years of treatment of ETV in a hypothetical
cohort of 1000 CHB patients; cirrhosis and hepatocarcinoma
(HCC) events were projected to 10 years. Clinical efﬁcacy data
was obtained from a recently published international random-
ized phase III trial in a group of HBeAg negative CHB patients.
The multivariate-adjusted relative risks for events were estimated
by Cox proportional hazards model from a recent Taiwan epi-
demiology study. Local health care costs including drug cost were
used. Cost of management of the different disease states were
adopted from a recently published local cost of illness study and
QALYs were calculated using the utility values obtained from
another recent local study. Hong Kong governmental population
statistics of life expectancy was used for the estimation.
RESULTS: Using a 5% discount rate for all projections, a 2-year
of ETV treatment would incur an extra drug cost of HKD23.5
million (about USD3 million, 1USD = 7.8HKD); yet about
HKD13.8 million (USD1.7 million) would be avoided in 10 years
time due to reduction in compensated and decompensated cir-
rhosis and HCC. The incremental cost-effectiveness for ETV is
about HKD24,000 (about USD3000) per life year saved and
HKD30,000 (about USD3800) per QALY saved. CONCLU-
SION: Using the US standard of USD50,000 per QALY in decid-
ing whether a therapy is cost-effective, the present study suggests
ETV to be a more cost-effective treatment relative to LVD for
CHB patients in the Hong Kong public sector.
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OBJECTIVES: To evaluate cost-effectiveness of entecavir (ETV)
vs. lamivudine (LVD) in treating CHB in Poland. METHODS:
A decision tree model was developed to project over a period of
10 years the number of cirrhosis (compensated and decompen-
sated) and hepatocellular carcinoma events based on serum HB
viral-DNA levels. Two hypothetical cohorts of CHB patients
treated for 2 years were studied: 1) nucleoside-naïve patients
treated with ETV (0.5 mg/day) vs. LVD (100 mg/day) and ade-
fovir (ADV) as salvage therapy in case of LVD resistance; and 2)
LVD-refractory patients treated with ETV (1 mg/day) vs. ADV
(10 mg/day). Effectiveness was measured as quality-adjusted life
year (QALY). Efﬁcacy data, the risk predicting models, utility
scores and medical costs for CHB disease stages were obtained
from published literatures. Life expectancy was estimated using
Polish life tables and published literature. A Polish health care
payer perspective was considered and a 5% discount rate was
used for both costs and outcomes. Sensitivity analyses to treat-
ment patterns, costs and utilities were performed. RESULTS:
Resistance to treatment with LVD was associated with lower efﬁ-
cacy and increased costs. In nucleoside-naïve HBeAg+ patients,
ETV compared with LVD therapy with ADV salvage saved
369,676/373,701 PLN and gained 28/30 QALYs for 100
men/women, respectively. For nucleoside-naïve HBeAg-patients,
savings were 185,066/187,564 PLN and QALYs gained 13/15
for 100 men/women, respectively. In LVD-refractory patients,
ETV therapy was associated with savings of 424,383/429,007
PLN and QALYs gained of 26/29 for 100 men/women, respec-
tively. Results were robust to sensitivity analyses. CONCLU-
SION: This cost-effectiveness analysis suggests that in the Polish
health care system, ETV dominates LVD to treat CHB in nucle-
oside-naïve and LVD-refractory patients. Due to differences in
life expectancy between men and women, cost-effectiveness
results are more favorable for women with CHB.
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COST-EFFECTIVENESS OF LINEZOLID IN GRAM-POSITIVE
INFECTIONS: CONSISTENCY OF ECONOMIC ADVANTAGE
FROM MULTIPLE HEALTH CARE SYSTEMS
Duttagupta S1, Sorensen SV2, Liu L1
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OBJECTIVES: Linezolid, an oxazolidinone antibiotic, has been
shown to be effective in the treatment of complicated skin and
soft-tissue infections (cSSTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP) caused by
methicillin-resistant Staphylococcus aureus (MRSA) in hospital-
ized patients. However, hospital use of linezolid has been limited
by high acquisition cost compared with other antibiotics. The
objective was to compare the consistency of cost-effectiveness
ﬁndings of linezolid across different health care systems.
METHODS: Separate studies were conducted in Brazil, Italy,
Germany, Spain, and the US to estimate the cost-effectiveness of
linezolid for the treatment of gram-positive infections. In all
studies (except US), a decision-analytic model was used to
predict the cost-effectiveness of linezolid vs vancomycin or
teicoplanin in each country. For the US, resource use data were
obtained from a multicenter trial. For all other countries, clini-
cal efﬁcacy data were obtained from multinational clinical trials,
cost data were based on published literature and local govern-
ment sources, and a Delphi panel comprising local experts pro-
vided input into health care resource utilization data. RESULTS:
In all health care systems, linezolid was cost-effective due to its
superior clinical cure and survival (in NP). In cSSTI, total treat-
ment costs were less expensive by $153 (Germany), $787 (Spain)
and $873 (US) mainly due to reduction in length of stay. In Italy,
treatment costs were similar (linezolid was $77 more). In VAP,
cost per life year saved was $380 in Spain and cost saving in
Brazil. Similarly, cost for life year gained for NP was $460.
CONCLUSION: All studies showed that despite higher acquisi-
tion cost, linezolid is either cost-saving or cost-effective for hos-
pitalized patients with gram-positive infections across multiple
health care systems due to its higher clinical efﬁcacy in terms of
cure and survival rates.
PIN14
A CANADIAN COST-EFFECTIVENESS ANALYSIS OF
DARUNAVIR FOR HIV INFECTION IN TREATMENT-
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OBJECTIVES: Darunavir (TMC114; DRV) is a novel protease
inhibitor (PI) with demonstrated superior efﬁcacy to currently
available PIs for the treatment of HIV infection in treatment-
experienced adults who have failed prior antiretroviral therapy.
We evaluated the cost-effectiveness (CE), from a Canadian
provincial Ministry of Health perspective, of ritonavir-boosted
DRV (DRV/r) plus an optimized background regimen (OBR)
compared to currently available PIs plus OBR (control).
METHODS: A Markov model with 3-month cycles was devel-
oped to follow patients through 6 possible health states deﬁned
by CD4 cell count ranges. Costs (in 2006 Canadian dollars) were
assumed to accrue based on estimates of health care services used
during each health state. Each health state also had an associ-
ated utility value. Cost, utility, and mortality data were estimated
from published Canadian sources. Transition probabilities were
calculated from clinical trials. Both costs and outcomes were dis-
counted at 5%/year. Two analyses were conducted: 1) incre-
mental cost/additional person with viral load <50 copies/mL at
48 weeks; 2) incremental lifetime cost/quality-adjusted life-year
(QALY) gained. Extensive sensitivity and variability (assessing
impact of practice patterns, population and model characteris-
tics) analyses were performed. RESULTS: DRV/r is associated
with a 36% absolute increase in probability of achieving viral
load <50 copies/mL at 48 weeks and a gain of 1.27 QALYs over
a lifetime. The incremental cost/additional person with viral load
<50 copies/mL was $9897; the incremental cost/QALY gained
was $30,907. Sensitivity and variability analyses showed results
were robust. For most of the credible uncertainty ranges, the CE
ratio remained less than $50,000/QALY gained. Variability
analyses showed CE ratios ranged $23,283–$34,667 depending
most heavily on the assumed amount of tipranavir use in the
model control arm and enfuvirtide use in the OBR. CONCLU-
SION: When compared to current standard of care, DRV/r plus
OBR is cost-effective in treatment-experienced adults who have
failed prior antiretroviral therapy.
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BACKGROUND: The cost-effectiveness of routine inﬂuenza vac-
cination in people over 65 is accepted. This study compares the
incremental cost-effectiveness of the MF59 adjuvanted vaccine
Fluad®* to non-adjuvanted vaccines in France in situations where
the circulating strain matches the strain prepared in the vaccine,
and also where there is antigenic drift—where the circulating
strain differs slightly from the one included in the vaccine.
METHODS: A decision analysis model was developed using evi-
